Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 16/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20152900 | 0.85 | RIPK1 (0.54) | RIPK1ALDH1A1KMT2APOLB | |
| SCHEMBL18248300 | 0.84 | RIPK1 (0.54) | RIPK1POLB | |
| Hydrochloric Acid SCHEMBL30018258 | 0.83 | RIPK1 (0.53) | RIPK1POLB | |
| SCHEMBL18248365 | 0.81 | RIPK1 (0.55) | RIPK1 | |
| SCHEMBL18248370 | 0.77 | RIPK1 (0.62) | RIPK1POLB | |
| SCHEMBL20152898 | 0.76 | RIPK1 (0.77) | RIPK1 | |
| SCHEMBL18248308 | 0.76 | RIPK1 (0.60) | RIPK1POLB | |
| SCHEMBL23830679 | 0.74 | RIPK1 (0.69) | RIPK1ALDH1A1POLB | |
| SCHEMBL22779612 | 0.74 | RIPK1 (0.62) | RIPK1ALDH1A1 | |
| SCHEMBL23146464 | 0.74 | RIPK1 (0.61) | RIPK1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134665-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134665-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K1 | RIPK1 414/4885ALDH1A1 1542/4885KMT2A 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.